CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Mats Hidestrand; Mikael Oscarson; Jarmo S. Salonen; Leena Nyman; Olavi Pelkonen; Miia Turpeinen; Magnus Ingelman-Sundberg

Research ArticleArticle

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg

Drug Metabolism and Disposition November 2001, 29 (11) 1480-1484;

Mats Hidestrand

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mikael Oscarson

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jarmo S. Salonen

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Leena Nyman

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Olavi Pelkonen

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Miia Turpeinen

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Magnus Ingelman-Sundberg

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Drug Metabolism and Disposition

Vol. 29, Issue 11

1 Nov 2001

Table of Contents
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Message Subject (Your Name) has forwarded a page to you from Drug Metabolism & Disposition

Message Body (Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Research ArticleArticle

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg

Drug Metabolism and Disposition November 1, 2001, 29 (11) 1480-1484;

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Research ArticleArticle

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg

Drug Metabolism and Disposition November 1, 2001, 29 (11) 1480-1484;

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
eLetters
PDF

Main menu

User menu

Search

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Plain text

Vertical Tabs

Jump to comment:

In this issue

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Citation Manager Formats

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Navigate

More Information

ASPET's Other Journals